GCKR rs7804194: Glucose, Triglycerides, and Liver Fat
The rs7804194 variant is a single-nucleotide polymorphism located within the glucokinase regulator (GCKR) gene locus on chromosome 2. Large-scale genome-wide association studies (GWAS) robustly link this locus to metabolic traits, specifically altering the balance between circulating fasting plasma glucose, serum triglycerides, and hepatic lipid storage. Inheriting the effect allele is associated with a distinctive metabolic trade-off characterized by lower fasting blood glucose alongside higher circulating triglyceride levels.
What each genotype means
Higher fasting glucose levels
This genotype is associated with slightly higher fasting plasma glucose levels compared to carriers of the T allele. Research indicates that while this genotype is linked to higher glucose, it is also associated with lower levels of plasma triglycerides and a potentially lower risk of hepatic fat accumulation.
This is the major genotype in many populations, carried by a significant portion of individuals of European and East Asian ancestry.
Mixed metabolic trait profile
Carrying one copy of the T allele is associated with an inverse relationship between glucose and lipid metabolism. Specifically, this genotype is linked to lower fasting plasma glucose levels but higher levels of serum triglycerides and an increased predisposition toward hepatic fat accumulation.
This heterozygous genotype is common, appearing in a large percentage of the population across European and East Asian ancestries.
Lower fasting glucose levels
This genotype is associated with the lowest fasting plasma glucose levels among the three groups. However, it is also strongly associated with higher plasma triglyceride levels and an increased risk of hepatic fat accumulation, reflecting the balancing act between glucose and lipid metabolism regulated by the GCKR protein.
This genotype is the minor variant, occurring less frequently than the CC or CT genotypes in most studied populations.
Understanding rs7804194 and the GCKR Gene
The single-nucleotide polymorphism rs7804194 resides within the GCKR gene region on human chromosome 2. This gene encodes the glucokinase regulatory protein (GKRP), an essential molecular controller expressed predominantly in hepatocytes. GKRP binds to and regulates glucokinase, the enzyme responsible for phosphorylating glucose to initiate glycolysis and glycogen synthesis in the liver. Under low-glucose conditions, GKRP sequesters glucokinase inside the cell nucleus in an inactive state, whereas rising glucose concentrations trigger its release into the cytoplasm. Variants in the GCKR locus, including rs7804194 and nearby linked markers such as rs780094 and rs1260326, subtly adjust this regulatory switch, altering how efficiently liver cells process incoming carbohydrates and channel metabolic intermediates into lipid synthesis pathways.
The Metabolic Trade-off: Glucose Versus Lipids
Genome-wide association studies catalog strong, reproducible statistical evidence linking common variation at GCKR to contrasting metabolic effects. Carrying the minor allele at rs7804194 is associated with slightly lower fasting blood glucose concentrations and modestly reduced risk of type 2 diabetes. However, this enhanced hepatic glucose clearance comes with a trade-off: increased hepatic de novo lipogenesis. As the liver processes more glucose, intermediate carbons are redirected into lipid production, leading to statistically higher fasting plasma triglyceride levels, elevated apolipoprotein B, and increased susceptibility to hepatic fat accumulation (non-alcoholic fatty liver disease or MASLD). These reciprocal associations highlight the complex homeostatic balance between carbohydrate utilization and lipid storage managed by hepatic GKRP activity.
Strength of Scientific and Epidemiological Evidence
The metabolic associations identified at the GCKR locus represent some of the most heavily replicated findings in human complex-trait genetics. Dozens of large international cohorts, such as the CHARGE Consortium and the Global Lipids Genetics Consortium, have confirmed genome-wide significant associations with fasting glycemic traits, blood lipid fractions, and hepatic steatosis. Functional genomic studies indicate that genetic variants in this region alter regulatory enhancer activity and GKRP protein binding dynamics. Because rs7804194 resides in strong linkage disequilibrium with other functionally characterized GCKR polymorphisms, it acts as a reliable tag for this locus-wide metabolic pattern across diverse population cohorts worldwide.
Population Frequency and Genetic Distribution
The rs7804194 variant is common across human populations globally. According to reference data in dbSNP and gnomAD, the minor allele frequency typically ranges between 35% and 42% in populations of European and East Asian ancestry, while also appearing at substantial frequencies in Hispanic and South Asian populations. Because the variant is so prevalent, millions of individuals carry either one or two copies of the effect allele. Its widespread occurrence indicates that carrying this variant does not cause an uncommon monogenic condition, but rather represents normal evolutionary variation in human energy storage and metabolic tuning.
Translating Genetic Findings into Personal Health Context
Genomic data regarding rs7804194 provide educational context about an individual's underlying metabolic architecture, but they do not constitute a clinical diagnosis. Carrying an allele linked to higher triglycerides or lower glucose does not guarantee abnormal laboratory results, nor does it replace standard metabolic screening. Environmental factors, including dietary sugar intake, alcohol consumption, overall body composition, and physical activity, play dominant roles in determining whether metabolic traits manifest clinically. Individuals interested in optimizing their cardiovascular and metabolic health should evaluate comprehensive lipid panels and glycemic markers in collaboration with a licensed healthcare provider rather than making lifestyle or medical adjustments based on genotype alone.
How common is this variant?
The minor allele frequency for rs7804194 ranges approximately from 0.35 to 0.42 across European and East Asian cohorts in the gnomAD database, with heterozygous and homozygous genotypes widely observed across global populations.
Frequently asked questions
Does carrying the rs7804194 variant mean I will develop fatty liver disease?
No, carrying rs7804194 is not a diagnosis and does not guarantee that you will develop fatty liver disease. The variant creates a modest statistical predisposition toward increased hepatic lipid storage, but overall lifestyle factors, diet, and physical activity strongly influence liver health.
Why does GCKR lower glucose while increasing triglycerides?
Variants in GCKR reduce the regulatory inhibition on hepatic glucokinase, allowing liver cells to absorb glucose from the bloodstream more rapidly. The excess glucose captured by the liver is subsequently converted into fatty acids via de novo lipogenesis, driving up circulating triglyceride levels.
Can rs7804194 predict my risk of type 2 diabetes?
Population studies show that the minor allele at rs7804194 is associated with slightly lower fasting blood glucose levels and a modest decrease in type 2 diabetes risk. However, diabetes risk is polygenic and heavily influenced by overall metabolic health, body mass index, and diet.
Should I modify my diet based on my GCKR genotype?
You should not make drastic changes to your diet solely based on a single genetic variant. While individuals with higher-attention genotypes may benefit from moderating refined carbohydrate intake to control triglycerides, any substantive nutritional changes should be reviewed with a registered dietitian or physician.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7804194?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in GCKR
A significant SNP identified through fine-mapping that demonstrates a consistent effect on triglyceride levels across different ancestral populations.
A well-replicated regulatory/intronic variant within GCKR strongly associated with variation in fasting serum triglycerides, glucose levels, and lipid metabolism.
This variant in the GCKR gene is strongly linked to altered glucokinase regulation, influencing fasting blood triglyceride and glucose levels.
GCKR P446L modulates the glucokinase regulatory protein and balances triglyceride and glucose levels.
This variant is associated with variations in fasting glucose and lipid levels, commonly studied in metabolic GWAS.